T
Ting Bao
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 93
Citations - 2439
Ting Bao is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Acupuncture. The author has an hindex of 20, co-authored 71 publications receiving 1614 citations. Previous affiliations of Ting Bao include Johns Hopkins Bayview Medical Center & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Aromatase, aromatase inhibitors, and breast cancer.
TL;DR: Three aromatase inhibitors (AIs) are now FDA approved and have been shown to be more effective than the antiestrogen tamoxifen and are well tolerated and are now a standard treatment for postmenopausal patients.
Journal ArticleDOI
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
TL;DR: The majority of long-term breast cancer survivors who received taxane-based chemotherapy reported CIPN symptoms; obesity was a significant risk factor; those with CIPn also reported increased psychological distress and falls.
Journal ArticleDOI
Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline
Gary H. Lyman,Heather Greenlee,Kari Bohlke,Ting Bao,Angela DeMichele,Gary E. Deng,Judith M. Fouladbakhsh,Brigitte Gil,Dawn L. Hershman,Sami Mansfield,Dawn M. Mussallem,Karen M. Mustian,Erin Price,Susan Rafte,Lorenzo Cohen +14 more
TL;DR: The SIO guideline addressed the use of integrative therapies for the management of symptoms and adverse effects of breast cancer treatment-related adverse effects, including anxiety and stress, mood disorders, fatigue, quality of life, and chemotherapy-induced nausea and vomiting.
Journal ArticleDOI
Manual lymphatic drainage for lymphedema following breast cancer treatment
Jeanette Ezzo,Eric Manheimer,Margaret L. McNeely,Doris Howell,Robert Weiss,Karin Johansson,Ting Bao,Linda Bily,Catherine Tuppo,Anne F. Williams,Didem Karadibak +10 more
TL;DR: To assess the efficacy and safety of MLD in treating breast cancer-related lymphedema, six trials were included and it was found that participants with mild-to-moderate BCRL were better responders to MLD than were moderate- to-severe participants.
Journal ArticleDOI
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
Bhavana Bhatnagar,Steven Gilmore,Olga Goloubeva,Colleen Pelser,Michelle Medeiros,Saranya Chumsri,Katherine Tkaczuk,Martin J. Edelman,Ting Bao +8 more
TL;DR: African-American patients, diabetics and subjects treated with paclitaxel had a higher risk for CIPN-associated dose reduction in the study, and limited literature is available on the prevalence and severity of dose reduction due to CIPn.